Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review
Martedì 10 novembre 2020
circa 1 minuti di lettura
Journal and Affiliations:
Pharmaceuticals, 10 novembre 2020
Giorgio Treglia, Clinica di Medicina nucleare e Centro PET/CT, Istituto di Imaging della Svizzera italiana, EOC, Bellinzona e Health Technology Assessment Unit, Academic Education, Research and Innovation Area, EOC, Bellinzona
Tags:
COVID-19
FDG
fluorodeoxyglucose
infection
PET
SARS-CoV-2
systematic review
Authors:
Giorgio Treglia